Introduction
This paper is concerned with certain fundamental problems in the evaluation of treatment. The data will be used as a practical example to illustrate the problems, rather than to give information about the comparative value of the drugs used. The data were obtained in the course of an investigation on the differences between those patients who responded and tho~e who did not respond to drugs. For this reason the material rel~ted to the evaluation of the drugs is derived from a control trial but not from a blind trial.
. The patients coming into the trial were dlagnos.ed a~suffering from a primary depressive disorder; they were not so ill tha~they needed~.c.T. Once the diag-nOSIS was determmed and the decision made to put the patient on drugs, they :v~re th~n randomly allotted to either ImIpramme or phenelzine. The assessment of their condition having been made and recorded by means of a rating scale (2) they were then seen as often as necessary, reassured about their condition and any possible side-effects, and a careful check kept on their consumption of the tablets. They were then assessed after two months on treatment and again after another two months. The criterion of improve1JoIent consisted of the post-treatment ratmg sc?r~. expressed as a percentage of the initial score. For various reasons which cannot be dealt with here this criterion was considered bette; than a plain final score, a difference score, or a regression score. With this criterion, a high score means a poor result and a low score means a good result. Complete recovery is shown as a zero score. The results show that imipramine has a slight advantage over phenelzine both at two months and at four months, but the difference is not statistically significant. It is of interest to note that improvement continues steadily with both drugs until the four months. Since the data for men and women had been kept separate, it was possible to analyze the data by means of a two-way analysis o~variance. The results suggest that the difference between the drugs is greater for women than for men. Even when a random allotment of patients to treatment has been made, it is always advisable to test whether the groups so formed are in fact reasonably alike. All sorts of items of information could be so examined, but from the common sense point of view, it is reasonable to confine tests to those variables which are likely to have some relation to the results of treatment. Table II shows the results of the comparison of the four groups on their initial score on the rating scale (which is a measure of the severity of their illness) and on an index number which is a measure of the pattern of symptoms: a high score signifies an agitated type of depression and a low score signifies a retarded type of depression. It is evident that the four groups are very much alike.
It is always possible that the amount of improvement is related to the original severity of the illness. Where the criterion is a difference-score, this follows from the nature of the score itself. The use of the proportional score is designed to eliminate this. It was decided to see how far this criterion had actually succeeded in eliminating this effect and therefore the correlations between initial score and the criterion calculated for all the four groups separately. The results show that in the case of patients treated by phenelzine the more severe cases did worse than the milder cases. For imipramine this is true only for women, but not true for men. Although the difference between the correlation coefficients for men and women are statistically significant, it is not permissible to select the largest differences in a table and do a test of statistical significance on it.~evertheless, the differences are large enough to give a warning note that there may be a difference between the response of men and women to imipramine.
There is some evidence that imipramine has a better effect on patients suffering from the retarded type of depression than from the anxious type (1) . There is also evidence, though it is still far from adequate, that the reverse may be true for phenelzine. Since the index number gives a quantified measure of the type of illness and the outcome of treatment is also quantified, it is possible to examine the relationship between type of illness and result of treatment by means of a correlation coefficient. Table IV shows that for phenelzine the results are in agreement with the hypothesis, although the correlations are too small to be statistically significant for the few cases. In the case of imipramine, the results show that for women the positive correlation is in agreement with accepted opinion, i.e. that the retarded type of patient does better than the anxious type. This is not true for the men. It would be unwise to draw firm conclusions from such a small number of cases, but the data reinforce the suggestion that men and women respond differently to imipramine. The difference between the response of the two sexes to treatment by imipramine has not previously been described, probably because previous work on the evaluation of this drug has not distinguished between the sexes, the two have always been combined into one group. Since in any unselected group of depressives there are many more women than men, the type of response of the women would predominate.
Further statistical tests of the data, which are not worth giving in detail, are as follows:-
The test of significance of the null hypothesis of covariance, i.e, that the covariances are alike for the four groups, give a probability of 10%. This is below the usual standards of significance, i.e. there is not enough evidence to suggest that the covariances differ. On the other hand, there is sufficient evidence to make one hesitate to accept the null hypothesis, i.e, it would be unwise to assume that the covariances are alike. One way of tackling this problem is to divide each of the four groups into two, those with high and those with low index scores. The eight groups can then be analyzed by a three-way analysis of variance. When this is done, the highest F ratio is for the threeway interaction, although this is not quite up to the usual standards of significance. The clinical meaning of a three-way interaction is demonstrated in the figure. Consider the effect of imipramine: the figure shows that women do worse than men in the agitated type of depression but this is reversed for the retarded type. When we turn to the effects of phenelzine we see that this reversal is again reversed.
.
Coneluslons
The only firm conclusion that can be drawn from the data is that the investigation should be repeated. If the results obtained were to be fully confirmed then this would signify that the appropriate choice of drug for the treatment of a depressed patient would depend not only on the type of illness but also on the sex of the patient.
Some Lessons
There is still a surpnsmg amount of ignorance on the nature and purpose of controlled trials. In particular, the function of the control series is little understood. It is still often thought that a control series consists of a group of patients who are not given treatment, or given a placebo or dummy tablet instead of treatment. Again and again one sees in the literature an apology made by the investigator that' in a controlled trial comparing two or more treatments, there is not included a group given only placebo. Such apologies are quite unnecessary and serve only to indicate that the investigator did not know what he was doing. When the results from a given treatment are reported, it is impossible to give a meaning to them unless some background information is available. For example, two investigators report on new treatments for two different disorders. The first reports a recovery rate of 80-100% and the second of 5%. These figures are meaningless until we have at least some information, for example, the diseases for which the treatments were given. The first treatment was for the common cold. Since we expect 100% recovery rate from the common cold, we are not impressed by the new treatment. The second disease was acute leukaemia and for this a genuine 5% recovery rate is a remarkable achievement.
The results of a treatment can only be given meaning by comparison with some sort of standard. The purpose of a controlled trial is to provide the standard. If we wish to compare a new treatment against the standard treatment, we give the new treatment to one group of patients and the old standard treatment to another group of patients. To ensure that the two groups are alike and there is no bias in the allotment of treatment, we make use of some method of 'random allotment' of treatment to the patients. If we wish to know whether a treatment is better than no treatment at all, then we give that treatment to one group of patients and no treatment to another group of patients. If we wish to know whether treatment A is better than treatment B, then we have two groups of patients, one given treatment A and the other given treatment B. If we wish to know whether treatment is better than nothing, then we have one group of patients given the treatment and another group of patients given nothing. The nature of the question asked determines the nature of the control group; and contrariwise, the nature of the control group determines the nature of the question asked.
It cannot be too often emphasized that a controlled trial is not necessarily a blind trial. If the criterion of change is such that it might be affected by the patient's knowledge of which treatment he was receiving, then it is necessary that the patient should not have such knowledge; this is the single blind trial. If the criterion of change is such that knowledge of the t~eatment given by the patient's psysiclans or other attendants could bias the results, then it is necessary for them also to be ignorant of the identity of the treatment given to an individual patient; this is the double blind trial. Where the criterion cannot be affected by such knowledge, e.g. when the criterion is a death rate, then there is no need for a controlled trial to be either singly or doubly blind (3) .
It is absolutely fundamental that where there is no control series, then a trial of a treatment can only give hypotheses for testing. It is often argued that general knowledge about previous cases is an adequate background for evaluating a treatment, but this ignores the fact that it is in general impossible to decide whether a particular series can strictly be compared with a previous series of cases. It is possible to put a simple question to the critics of controlled trials:let them consider the results obtained from a controlled trial, but ignore the results obtained from the control group. Can they demonstrate that they can derive better conclusions from half the information than from all of it?
If ignorant criticism of controlled trials is dismissed, there still remains a certain amount of criticism which is perfectly valid: that controlled trials are not helpful to clinical practice. It is regrettably true that most controlled trials are still at a very primitive level. Particularly in the field of psychiatry, the general procedure in controlled trials is to take a group of patients suffering from some or other broad diagnostic category, (even this may be omitted), give them appropriate treatments and then evaluate the results. The conclusions from such a trial are relevant only to patients selected in the same sort of way, given that particular dose of treatment used in the trial, and under the conditions it was given, and using the particular criterion used. With these limitations, it can be concluded that, provided A was found significantly better than B, then in the long run if such patients are given treatment A, the results on the average will be better than if they had been given B. This is a very far cry from the clinicians' problem: what is the best treatment for a given patient? But this is only the first of the problems facing the clinician. There are at least four other questions that the practising physician asks of any treatment:-How good will it be How much better will this treatment be than other treatments? What are the risks associated with this treatment? How much worse off will the patient be if this treatment is not a success in his case? All practising physicians will agree that these questions cannot be ignored, but the number of trials of treatments which give information that can answer them is negligible. It might be argued that it is not surprising that information on these points is not available for new treatments, since in any case such information is not often available for standard treatments which have been in use for a long period of time. Of course this is true, and it brings home to us that the application of scientific methods to the evaluation of treatments has only just begun.
Resume
Une epreuve therapeutique de la phenelzine et de l'imipramine sur un groupe de deprimes sert de point de depart aux conclusions de l'auteur. Notant en particulier que l'effet du traitement semble varier non seulement selon le genre de depression, mais aussi selon le sexe (et qu'ainsi la preponderance de l'element feminin chez les deprimes peut fausser les resultats) on peut d'abord dire que la seule conclusion definitive est que l'experience n'est pas concluante et devrait etre rejetee.
On se meprend parfois sur la nature ou Ie but du groupe temoin: celui-ci est necessaire pour fournir un point de comparaison mais on ne compare pas necessairement avec l'absence de traitement ou avec un placebo: II faut que Ie groupe ternoin et l'hypothese a verifier correspondent. II est aussi note que la methode a double insu n'est pas un critere absolu de validite.
II n'en reste pas moins que la plupart des essais de verification clinique en sont encore a un niveau primitif et n'offrent que tres rarement des indications precises pour un malade donne, suggerant plutot une probabilite (statistique) plus grande d'une amelioration plus marquee chez un groupe de malades defini, selon des criteres tres restreints.
Les questions fondamentales: 1) Que vaut ce traitement? 2) Qu'offre-t-il de mieux que les autres traitements? 3) quels en sont les risques? et 4) Que peut-on redouter pour le malade si le traitement n'est pas efficace? demeurent le plus souvent sans reponse, merne dans le cas de therapeutiques etablies depuis longtemps. L'application de methodes scientifiques a l'essai therapeutique ne fait que commencer.
